ESC Premium Access

How good/bad are we in treating lipids

Event: ESC CONGRESS 2019
Topic: Lipids
Session type: Moderated Posters
Date: 1 September 2019
Time: 10:05 - 10:55


7 presentations in this session

Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort

Speaker: Doctor B. Gencer (Geneva, CH)

Attributable risk proportion of uncontrolled low-density lipoprotein cholesterol in recurrent acute coronary syndromes

Speaker: Doctor E. Martinez Rey-Ranal (Elche, ES)

Statin treatment in children with familial hypercholesterolemia in Scandinavia

Speaker: Doctor K. Svendsen (Oslo, NO)

Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden

Speaker: Doctor E. Hagstrom (Uppsala, SE)

Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES

Speaker: Professor G. Schwartz (Aurora, US)

Remnant lipoprotein is a residual risk of future cardiovascular events in patients with stable coronary artery disease and on statin LDL-cholesterol levels less than 70 mg/dl

Speaker: Doctor Y. Fujihara (Kofu, JP)

Impact of history of vascular disease on lipoprotein(a) associations with cardiovascular outcomes: a Mendelian randomisation study in 283,658 UK Biobank participants

Speaker: Doctor A. Stiby (Oxford, GB)

7 speakers from this session

Doctor Baris Gencer

Geneva University Hospital, Cardiology Division, Geneva (Switzerland)
0 follower

Doctor Elias Martinez Rey-Ranal

University Miguel Hernandez, Elche (Spain)
0 follower

Doctor Karianne Svendsen

Oslo University Hospital, Oslo (Norway)
0 follower

Doctor Emil Hagstrom

Uppsala University, UCR-Uppsala Clinical Research Center, Uppsala (Sweden)
1 presentation
0 follower

Professor Gregory Schwartz

University of Colorado School of Medicine, Aurora (United States of America)
2 presentations
0 follower

Doctor Yuki Fujihara

Kofu Jonan Hospital, Kofu (Japan)
0 follower

Doctor Alexander Stiby

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)
0 follower

This platform is supported by

logo Novo Nordisk